13F Holdings
中文EN

XCUR EXICURE, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1698530 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-97.7%
TTM net income YoY-235.0%
TTM EPS YoY65.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,228.2%
Net margin-801.4%
FCF margin—
EBITDA margin-1,222.6%

Returns

ROE-132.6%
ROA-34.0%
ROIC (approx.)-326.7%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets85.5%
Debt / equity0.00x
Current ratio0.71x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$500,000$0$28.83M-$483,000
R&D expense$3.29M$0$1.42M$19.77M$48.98M
SG&A expense$6.83M$5.45M$11.71M$10.89M$13.09M
Operating income-$4.23M-$12.23M-$15.00M-$1.83M-$62.55M
Interest expense$1,000$18,000$0$595,000$1.69M
Pretax income-$5.58M-$9.69M-$16.91M-$2.37M-$64.10M
Income tax-$634,000$8,000$0$209,000$0
Net income-$4.95M-$9.70M-$16.91M-$2.58M-$64.10M
EBITDA-$3.99M-$12.20M-$14.36M-$668,000-$61.43M
EPS (basic)-0.79-4.75-10.55-0.56-21.70
EPS (diluted)-0.79-4.75-10.55-0.56-21.70
Weighted avg. shares (diluted)6.30M2.04M1.60M4.62M2.95M
Balance sheet
Cash & equivalents$3.75M$12.51M$2.02M$9.78M$43.84M
Short-term investments———$0$4.50M
Receivables————$0
Current assets$4.62M$13.67M$2.02M$10.05M$43.67M
PP&E, net$306,000$26,000$54,000$2.53M$3.93M
Goodwill$4.40M$0———
Intangibles$3.78M$0———
Total assets$14.04M$15.06M$11.58M$23.33M$64.87M
Current liabilities$3.89M$3.07M$2.51M$1.64M$34.07M
Short-term debt——$0$0$6.87M
Long-term debt————$0
Total debt————$6.87M
Total liabilities$10.12M$8.28M$8.55M$8.41M$53.64M
Shareholders' equity$3.93M$6.77M$3.03M$14.92M$11.23M
Net debt————-$36.97M
Shares outstanding6.37M6.03M1.83M4.97M3.63M
Cash flow statement
Operating cash flow-$8.55M-$2.91M-$10.36M-$35.66M-$34.82M
Capital expenditure$1,000$0$0$10,000$968,000
Free cash flow-$8.56M-$2.91M-$10.36M-$35.67M-$35.79M
Investing cash flow-$1.81M$0-$1.08M$4.70M$43.09M
Financing cash flow$1.60M$13.40M$3.67M-$3.10M$1.12M
Depreciation & amortization$242,000$28,000$634,000$1.16M$1.12M
Stock-based compensation$2,000$22,000$1.35M$1.37M$2.94M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.